Abstract
Harrison et al. have attempted to validate Part II of the Unified Parkinson's Disease Rating Scale (UPDRS II) as a medication-independent measure of disease progression. The authors collected cross-sectional data from a cohort of 888 patients with idiopathic Parkinson disease, and they found a robust association between UPDRS II scores and disease duration. Other variables considered were the patients' levodopa status, age at disease onset, and scores on UPDRS I, II and III. The results suggest that a single UPDRS II measurement might be a good indicator of progression at a given time point, irrespective of the current disease-related circumstances. This concept is attractive in its simplicity and patient-centeredness. However, this evidence came from a single-center, retrospective study, the statistical model was constructed using a nonvalidated surrogate as an independent variable, and no external replication was conducted. Until further confirmation, therefore, Harrison et al.'s proposal can only be considered to be a working hypothesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
MB Harrison et al. (2008) UPDRS activity of daily living score as a marker of Parkinson's disease progression. Mov Disord [10.1002/mds.22335]
Marras C et al. (2002) Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59: 1724–1728
Sampaio C and Rascol O (2006) Disease-modifying strategies in Parkinson's disease. In Parkinson's Disease and Movement Disorders, edn 5, 102–109 (Eds Tolosa E and Jankovic J) Philadelphia: Lippincott Williams & Wilkins
Eckert T et al. (2007) Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 6: 926–932
Goetz CG et al. (2003) Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 18: 1455–1458
Gallagher DA and Schrag A (2008) Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 22: 563–586
Post B et al. (2007) Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord 22: 1839–1851
Shulman LM et al. (2008) The evolution of disability in Parkinson disease. Mov Disord 23: 790–796
Goetz CG et al. (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23: 2129–2170
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sampaio, C. Can focusing on UPDRS Part II make assessments of Parkinson disease progression more efficient?. Nat Rev Neurol 5, 130–131 (2009). https://doi.org/10.1038/ncpneuro1049
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro1049